ADVFN ADVFN

Hot Features

Icon for alerts 登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
Nxera Pharma Company Ltd (PK)

Nxera Pharma Company Ltd (PK) (SOLTF)

6.00
-0.37
(-5.81%)
終了 7月4日 5:00AM

Nxera Pharma Company Ltd (PK) (SOLTF) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

主要統計と詳細

通貨
6.00
( -5.81% )
買値
5.35
売値
6.54
出来高
1,150
6.00 日の範囲 6.00
4.90 52 週間の範囲 7.94
時価総額
前日終値
6.37
始値
6.00
時刻
1150
@
6
最終取引時間
財務取引量
US$ 6,900
VWAP
6.00
平均取引量 (3 か月)
US$ 1,058,156
発行済株式数
92,612,178
配当利回り
PER
-8.97
1 株当たり利益 (EPS)
-110.34
歳入
34.23B
純利益
-9.98B

Nxera Pharma Company Ltd (PK) について

Nxera Pharma Co., Ltd. operates as a biopharmaceutical company, engages in drug discovery and development in Japan, the United States, Germany, Switzerland, Bermuda, the United Kingdom, and internationally. The company offers NxWave, a GPCR-targeted structure-based drug discovery platform; PIVLAZ fo... Nxera Pharma Co., Ltd. operates as a biopharmaceutical company, engages in drug discovery and development in Japan, the United States, Germany, Switzerland, Bermuda, the United Kingdom, and internationally. The company offers NxWave, a GPCR-targeted structure-based drug discovery platform; PIVLAZ for the cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aSAH; and QUVIVIQ for insomnia. It develops NBI-1117568, an muscarinic M4 agonist in phase 3 trial for schizophrenia, dementia and other neuropsychiatric disorders; ORX750, an OX2 agonist for narcolepsy, idiopathic hypersomnia, and other sleep-wake disorders; NBI-1117570, a dual muscarinic M1/M4 agonist; and HTL0039732, an EP4 antagonist immunotherapy drug. The company’s products in phase 1 trial include PF-07054894, a CCR6 antagonist and NXE0033744, an EP4 agonist for inflammatory bowel disease; PF-07258669, a MC4 antagonist for anorexia; NBI-1117569, a muscarinic M4-preferring agonist, and NBI-1117567, a muscarinic M1 agonist for major central nervous system disorders; TMP-301, a mGlu5 NAM for substance use disorders; and NXE0048149, a GPR52 agonist for schizophrenia. Its products in preclinical trial comprise KY1051, a CXCR4 mAb for immuno-oncology; and NXE0027477, a GPR35 agonist for inflammatory bowel disease and GI disorders. The company also develops other discovery-stage drugs. It has strategic collaborations with Tempero Bio, Pharmenable Therapeutics, Antiverse, Sanofi, Cancer Research UK, Centessa Pharmaceuticals, Lilly, AbbVie, Genentech, Pfizer, Neurocrine Biosciences, Antiverse, and Novartis International AG. The company was formerly known as Sosei Group Corporation. Nxera Pharma Co., Ltd. was incorporated in 1990 and is headquartered in Minato, Japan. 詳細を表示

セクター
Healthcare
業界
Biotechnology & Life Sciences
ウェブサイト
本社
Minato, Japan
設立
1990
Nxera Pharma Company Ltd (PK) is listed in the Healthcare sector of the その他OTC with ticker SOLTF. The last closing price for Nxera Pharma (PK) was US$6.37. Over the last year, Nxera Pharma (PK) shares have traded in a share price range of US$ 4.90 to US$ 7.94.

Nxera Pharma (PK) currently has 92,612,178 shares in issue. The market capitalisation of Nxera Pharma (PK) is US$555.67 million. Nxera Pharma (PK) has a price to earnings ratio (PE ratio) of -8.97.
期間 †前日比前日比 %始値高値安値平均出来高VWAP
10006000CS
4-0.185-2.991107518196.1856.3765006.2035CS
12-0.53-8.116385911186.537.945.5161876.4066779CS
260.8115.60693641625.197.945.1543026.38407472CS
52-0.2-3.225806451616.27.944.919136.31136843CS
156-4.38-42.196531791910.3813.524.912828.55212333CS
260-10.3203-63.23596992716.320322.7824.9144411.29736742CS

SOLTF - Frequently Asked Questions (FAQ)

What is the current Nxera Pharma Company Ltd (PK) share price?
The current share price of Nxera Pharma Company Ltd (PK) is US$ 6.00
How many Nxera Pharma Company Ltd (PK) shares are in issue?
Nxera Pharma Company Ltd (PK) has 92,612,178 shares in issue
What is the market cap of Nxera Pharma Company Ltd (PK)?
The market capitalisation of Nxera Pharma Company Ltd (PK) is USD 555.67M
What is the 1 year trading range for Nxera Pharma Company Ltd (PK) share price?
Nxera Pharma Company Ltd (PK) has traded in the range of US$ 4.90 to US$ 7.94 during the past year
What is the PE ratio of Nxera Pharma Company Ltd (PK)?
The price to earnings ratio of Nxera Pharma Company Ltd (PK) is -8.97
What is the cash to sales ratio of Nxera Pharma Company Ltd (PK)?
The cash to sales ratio of Nxera Pharma Company Ltd (PK) is 2.68
What is the registered address of Nxera Pharma Company Ltd (PK)?
The registered address for Nxera Pharma Company Ltd (PK) is Midtown East, Minato, Tokyo, 107-0052
What is the Nxera Pharma Company Ltd (PK) website address?
The website address for Nxera Pharma Company Ltd (PK) is www.nxera.life
Which industry sector does Nxera Pharma Company Ltd (PK) operate in?
Nxera Pharma Company Ltd (PK) operates in the Biotechnology & Life Sciences sector

SOLTF 取引

さらに

取引は遅延しています

リアルタイムの取引を取得するには、アカウントをアップグレードしてください

リアルタイムにアップグレード

最近閲覧した銘柄

Delayed Upgrade Clock